CALLISTO TO BEGIN ATIPRIMOD STUDY

A A

Callisto Pharmaceuticals will initiate a single-agent Phase II clinical trial of Atiprimod in advanced carcinoid cancer patients.

Originally planned as a Phase I/IIa trial, the decision to proceed directly to Phase II was based on a careful review of the Atiprimod safety and toxicity data obtained from the two ongoing trials of Atiprimod in advanced cancer and multiple myeloma patients, respectively.

Based on these data, a fixed dosing regimen has been finalized for the planned single-agent Phase II trial in advanced carcinoid cancer patients.